Page last updated: 2024-11-06

4-pentenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-pentenoic acid, also known as trans-2-butenoic acid, is an organic compound with the formula CH3CH=CHCH2COOH. It is a colorless liquid with a pungent odor. It is used in the synthesis of various pharmaceuticals, including anti-inflammatory drugs and anticonvulsants. It is also used as a flavoring agent and in the production of polymers. 4-pentenoic acid is a valuable building block in organic synthesis due to its reactive double bond and carboxylic acid group. Research on 4-pentenoic acid is ongoing, focusing on its potential applications in various fields, including medicine, agriculture, and industry. The compound's biological activity, its ability to interact with enzymes and receptors, and its potential for use in the development of new therapeutic agents are actively being investigated.'

4-pentenoic acid: inhibitor of fatty acid oxidation; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pent-4-enoic acid : A pentenoic acid having the double bond at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID61138
CHEMBL ID3185583
CHEBI ID35936
SCHEMBL ID13341412
SCHEMBL ID115342
MeSH IDM0054785

Synonyms (66)

Synonym
nsc-20944
nsc20944
delta 4-pentenoic acid
einecs 209-732-7
nsc 9000
brn 1633696
fema no. 2843
nsc 20944
4-penten-1-oic acid
allylessigsaeure
4-pentenic acid
CHEBI:35936 ,
delta(4)-pentenoic acid
4-pentensaeure
3-vinylpropionic acid
4 pa
591-80-0
4-pentenoic acid
wln: qv3u1
nsc9000
pent-4-enoic acid
allylacetic acid
.delta.4-pentenoic acid
nsc-9000
inchi=1/c5h8o2/c1-2-3-4-5(6)7/h2h,1,3-4h2,(h,6,7
4-pentenoic acid, >=98%, stabilized, fg
allyl acetic acid
c5:1n-1
LMFA01030007
4-pentenoic acid, 97%
P0645
NCGC00188966-01
EN300-64825
NCGC00255889-01
cas-591-80-0
tox21_302069
dtxsid0044448 ,
dtxcid8024448
AKOS006221010
4-02-00-01542 (beilstein handbook reference)
unii-d4s77y29fb
d4s77y29fb ,
STL280305
FT-0676299
S6268
SCHEMBL13341412
SCHEMBL115342
BBL027458
4-pentenoic acid [fhfi]
CHEMBL3185583
mfcd00004408
J-519555
CS-W009138
F2190-0007
delta4-pentenoic acid
3-butene-1-carboxylic acid
fema 2843
Q27116641
AS-11763
AMY12553
HY-Y0624
O12040
pent-4-enoicacid
4-pentenoic aicd
Z995028722
PD124022

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Male Sprague-Dawley rats (150-180 g, 4 rats per group) were dosed ip with 4-ene VPA (0."( Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Abbott, FS; Borel, AG; Fujimiya, T; Tang, W,
)
0.13
" Intraperitoneal administration of 4-pentenoic acid was performed once daily during seven days, the used dosage was 20mg/kg."( [ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE SYNDROME IN RATS].
Antelava, N; Ghonghadze, M; Liluashvili, K; Okujava, M; Pachkoria, K, 2017
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pentenoic acidAny C5, straight-chain, monounsaturated fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)30.00005.00005.00005.0000AID1341023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (53.95)18.7374
1990's15 (19.74)18.2507
2000's9 (11.84)29.6817
2010's11 (14.47)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.68 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other82 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]